These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Hydroa Vacciniforme-like Skin Lesions in Epstein-Barr-Virus-associated T-cell Lymphoproliferation with Subsequent Development of Aggressive NK/T-cell Lymphoma. Toksoy A; Strifler S; Benoit S; Grigoleit GU; Knop S; Mielke S; Buder-Bakhaya K; Roth S; Goebeler M; Rosenwald A; Geissinger E; Wobser M Acta Derm Venereol; 2017 Mar; 97(3):379-380. PubMed ID: 27826612 [No Abstract] [Full Text] [Related]
9. Hydroa Vacciniforme-like Lymphoproliferative disorder in an adult invades the liver and bone marrow with clear pathological evidence: a case report and literature review. Wang X; Wang P; Wang A; Xu Y; Wang L; Chen Z BMC Infect Dis; 2021 Jan; 21(1):17. PubMed ID: 33407199 [TBL] [Abstract][Full Text] [Related]
10. Hydroa vacciniforme-like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China. Wang X; Liang Y; Yang Y; Li W; Wang G; Wang S; Li Y; Zhang M J Dermatol; 2021 Sep; 48(9):1315-1326. PubMed ID: 33982815 [TBL] [Abstract][Full Text] [Related]
11. Antiviral treatment of a boy with EBV-associated hydroa vacciniforme. Pahlow Mose A; Fisker N; Clemmensen O; Bygum A BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25422336 [TBL] [Abstract][Full Text] [Related]
12. Hydroa vacciniforme-like lymphoproliferative disorder: Clinicopathologic study of 41 cases. Liu Y; Ma C; Wang G; Wang L J Am Acad Dermatol; 2019 Aug; 81(2):534-540. PubMed ID: 30654082 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases. Guo N; Chen Y; Wang Y; Huang Y; Feng Y; Li M; Rao H Diagn Pathol; 2019 Jul; 14(1):82. PubMed ID: 31315684 [TBL] [Abstract][Full Text] [Related]
15. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. Iwatsuki K; Ohtsuka M; Akiba H; Kaneko F J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):283-4. PubMed ID: 10025766 [No Abstract] [Full Text] [Related]
16. Hydroa vacciniforme-like lymphoproliferative disorder: A retrospective study on clinicopathological characteristics of 32 cases. Xu W; Tan J; Cai C; Lei L; Cao X; Zhou H; Xu M Pediatr Dermatol; 2022 May; 39(3):372-375. PubMed ID: 35194837 [TBL] [Abstract][Full Text] [Related]
17. Hydroa Vacciniforme-Like EBV-Positive Cutaneous T-Cell Lymphoma, First Report of 2 Cases in Ecuador. Montalvo N; Redrobán L Am J Dermatopathol; 2016 May; 38(5):e57-9. PubMed ID: 26913846 [TBL] [Abstract][Full Text] [Related]
18. Comparative Study of the Clinical Pathology, Immunophenotype, Epstein-Barr Virus Infection Status, and Gene Rearrangements in Adult and Child Patients With Hydroa Vacciniforme-Like Lymphoproliferative Disorder. Wen PF; Zhang M; Wang TT; Liu HJ; Zhang WY; Liu WP; Wang L Am J Dermatopathol; 2019 Jan; 41(1):7-15. PubMed ID: 30085959 [TBL] [Abstract][Full Text] [Related]
19. Artificial reproduction of atypical hydRoa vacciniforme caused by latent EpStein-Barr virus infection. Heo EP; Park SH; Kim TH Int J Dermatol; 2003 Jun; 42(6):476-9. PubMed ID: 12854510 [TBL] [Abstract][Full Text] [Related]